A functional map of NFκB signaling identifies novel modulators and multiple system controls by Halsey, Thomas A et al.
Genome Biology 2007, 8:R104
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Open Access 2007 Halsey et al. Volume 8, Issue 6, Article R104 Research
A functional map of NFκB signaling identifies novel modulators and 
multiple system controls
Thomas A Halsey*§, Longlong Yang*, John R Walker†, John B Hogenesch‡ 
and Russell S Thomas*
Addresses: *The Hamner Institutes for Health Sciences, 6 Davis Drive, PO Box 12137, Research Triangle Park, NC 27709-2137, USA. †Genomics 
Institute of the Novartis Research Foundation, 10675 John J. Hopkins Drive, San Diego, CA 92121, USA. ‡Institute for Translational Medicine 
and Therapeutics, 810 Biomedical Research Building, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, PA 
19104-6160, USA. §Almac Diagnostics, 801-1 Capitola Drive, Durham, NC 27713, USA. 
Correspondence: Russell S Thomas. Email: rthomas@thehamner.org
© 2007 Thomas et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which 
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Modulators of NFκB signaling <p>Using cell-based genomic screens and functional assays, positive and negative modulators of NFκB signaling were identified and  mapped onto the known NFκB signaling cascade.</p>
Abstract
Background: The network of signaling pathways that leads to activation of the NFκB transcription
factors is a branched structure with different inputs and cross-coupling with other signaling
pathways. How these signals are integrated to produce specific, yet diverse responses is not clearly
understood. To identify the components and structural features of the NFκB network, a series of
cell-based, genomic screens was performed using a library of approximately 14,500 full-length
genes.
Results: A total of 154 positive and 88 negative modulators of NFκB signaling were identified.
Using a series of dominant-negative constructs and functional assays, these modulators were
mapped to the known NFκB signaling cascade. Most of the positive modulators acted upstream of
the IκB kinase complex, supporting previous observations that the IκB kinases represent the
primary point of convergence in the network. A number of negative modulators were localized
downstream of the IκB kinase β (IKBKB) subunit, suggesting that they form an additional layer of
negative control within the system. The expression of the modulators at the RNA level was
distributed disproportionately across tissues, providing flexibility in network structure, and the
number of positive and negative modulators present in a given tissue was highly correlated,
suggesting that positive and negative regulation is balanced at the tissue level.
Conclusion: The relative locations of the modulators are consistent with an hourglass structure
for the NFκB network that is characteristic of robust systems. The tissue distribution of the
modulators and downstream location of the negative modulators serve as layers of control within
the system that allow differential responses to different stimuli.
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Background
The NFκB transcription factor represents a collection of
dimeric complexes from the NFκB/Rel family. The transcrip-
tional complexes regulate a broad spectrum of genes that
function in a variety of key biological processes [1]. At the net-
work level, the NFκB signaling pathway is a branched struc-
ture with a variety of inputs that include proinflammatory
cytokines, T- and B-cell receptors, growth factors, UV radia-
tion, and pathogen-associated signals (for example, bacterial
lipopolysaccharide (LPS)). The various branches within the
NFκB pathway are all associated with different cascades of
signaling events that eventually converge at a core set of IκB
kinases (IKKs). Historically, the branches have been organ-
ized into canonical and atypical classes. Among the branches
in the canonical class, stimulation by ligands such as tumor
necrosis factor-α (TNF), interleukin-1 (IL1), or LPS leads to
signaling events that activate the IκB kinase (IKK) complex
containing the CHUK (IKKα) and IKBKB (IKKβ) catalytic
subunits along with the IKBKG (IKKγ) regulatory subunit [2].
The activated IKK complex phosphorylates the inhibitory IκB
proteins, leading to their ubiquitination and degradation by
the 26S proteosome [2]. In the branches classified as atypical,
stimulation is limited to a smaller subset of NFκB activators
such as LTB and TNFSF13B. Signal initiation is followed by a
series of signaling events that activate CHUK homodimers
[3,4]. The CHUK homodimers phosphorylate the inhibitory
NFKB2 precursor, leading to processing into active NFKB2
and dimerization with RELB [3-5].
Despite the breadth of knowledge about NFκB signaling,
details are still being discovered about how other signaling
pathways interconnect within the greater NFκB network and
how various signaling inputs are integrated to form different
outputs. A variety of signaling pathways and subsystems are
known to cross-couple with the NFκB pathway at different
nodal points and modulate NFκB signaling. Examples of
cross-coupling include AP-1 [6], HSF1 [7], γ-interferon [8],
small GTPases [9], and PI3K [9]. The prevalence of cross-cou-
pling, together with the branched structure of the NFκB net-
work, results in a complex, interconnecting system whose
structure is both context and tissue dependent. A previous
study of the Toll-like receptor (TLR) branch of the NFκB net-
work suggested that the extent of cross-coupling within this
network provides the capability for the system to generate dif-
ferential responses to different stimuli [9].
To uncover the various genes and structural features involved
in the extended NFκB signaling network, several research
groups have applied advanced genomic and proteomic tech-
nologies. In one study, a large-scale full-length gene screen
was performed to identify activators of the NFκB and MAP
kinase (MAPK) pathways [10]. The investigators showed that
a significant number of activators were shared between the
two pathways [10]. Other studies have utilized RNA interfer-
ence [11,12] and protein-interaction measurements [12] to
identify functional and physical modulators of NFκB. In the
present study, the greater NFκB signaling network was exper-
imentally interrogated using a series of high-coverage gain-
of-function and loss-of-function genomic screens containing
14,500 full-length mouse and human genes. The genomic
screens were used to comprehensively identify both positive
and negative modulators of the NFκB pathway. Following the
initial screens, the positive and negative modulators were
mapped to specific locations in the NFκB pathway by screen-
ing them in tandem with a series of dominant-negative and
constitutively active mutants of key NFκB regulators. The rel-
ative placement of the modulators within the network and
their distribution across tissues were used to identify the mul-
tiple system controls within the NFκB network that ulti-
mately influence the specificity and diversity of the response.
Results
Identification of positive NFκB modulators using gain-
of-function full-length gene screens
To identify potential positive modulators, approximately
14,500 mouse and human full-length genes were screened for
their ability to activate an NFκB luciferase reporter. Individ-
ual genes were transfected into HEK-293T cells together with
the NFκB reporter and a constitutively expressed DsRed flu-
orescent protein using high-throughput transfection methods
(Figure 1). In the initial screen, 183 genes activated the NFκB
reporter greater than three-fold when normalized to the fluo-
rescent transfection control and had luciferase values greater
than 5 standard deviations (SD) from the experimental mean.
These genes were rearrayed and screened in triplicate to con-
firm activation of the NFκB reporter. Eighty-four percent
( 1 5 4  g e n e s )  o f  t h e  o r i g i n a l  p o s i t i v e  m o d u l a t o r s  w e r e  c o n -
firmed in these studies on the basis of an average three-fold
activation and an adjusted p value of less than 0.05. Of these
154 genes, 45 have been previously shown to modulate NFκB
signaling (Additional data file 1).
Among the known NFκB modulators, genes within both the
canonical and atypical NFκB signaling branches were identi-
fied, including known receptor ligands (TNF, IL1B, and LTA),
TNF receptors (TNFRSF1A,  TNFRSF10A,  TNFRSF11A,
TNFRSF12A, TNFRSF25, and TNFRSF10B), B-cell receptor
(CD40), adaptor proteins (TIRAP, MYD88, and FADD), TNF
receptor-associated factors (TRAF2 and TRAF5), members of
the NFκB transcriptional complex (RELA,  RELB, and
NFKB1), and others. The known positive modulators were
mapped to the canonical TNF, IL1, B-cell receptor, and T-cell
receptor signaling pathways (Additional data files 5 and 6).
The functional breakdown of the positive modulators is
shown in Figure 2a. The breakdown contains a diverse array
of categories that reflect the wide range of stimuli capable of
activating NFκB and potential cross-talk with other signaling
pathways.http://genomebiology.com/2007/8/6/R104 Genome Biology 2007,     Volume 8, Issue 6, Article R104       Halsey et al. R104.3
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Identification of negative NFκB modulators using loss-
of-function full-length gene screens
In order to identify inhibitors of NFκB activity, full-length
cDNAs were introduced into HEK-293T cells as described in
the preceding section and the cells were incubated in the pres-
ence of either TNF or IL1 (Figure 1). A total of 235 genes were
identified that reduced NFκB reporter activity greater than
three-fold when normalized to the fluorescent transfection
control and had luciferase values less than 5 SD from the
experimental mean. These genes were rearrayed and
screened in replicate to confirm the reduction of the NFκB
reporter activity when exposed to either TNF or IL1. Forty-
four percent (104 genes) of the original negative modulators
were confirmed in these studies based on an average three-
fold reduction and an adjusted p  value of less than 0.05
(Additional data file 2). To exclude nonspecific negative mod-
ulators, an identical assay was performed using the glucocor-
ticoid response element as the reporter and dexamethasone
as the stimulus. Sixteen genes that showed inhibition of
reporter activity in both screens were labeled as 'general
inhibitors' and were removed from subsequent analysis. For
the remaining 88 negative modulators, the functional break-
down is shown in Figure 2b. The breakdown was less diverse
than with the positive modulators and had a relatively high
percentage of genes related to DNA binding and transcrip-
tional activity, suggesting that a number of the negative mod-
ulators act downstream in the pathway.
Among the 88 negative modulators, 16 have been previously
shown to negatively regulate the NFκB pathway; they include
genes such as NFKBIB (IκBβ) [2], NFKBIE (IκBε) [2], PIAS4
[13], and RHOB [14]. The known negative modulators were
also mapped to the canonical TNF, IL1, B-cell receptor, and T-
cell receptor signaling pathways (see Additional data files 5
and 6). Several genes identified as negative modulators in our
s c r e e n  h a v e  b e e n  p r e v i o u s l y  s h o w n  t o  p o s i t i v e l y  r e g u l a t e
NFκB and three genes (GPD1, TRAF2, and TSPAN13) were
identified as both positive and negative modulators in our
screens (see Additional data files 1 and 2). For most of the
genes previously shown to be positive regulators, it is unclear
why they are negative modulators in our system. One possi-
bility is simple methodological differences. For example,
some genes previously shown to positively modulate NFκB
were identified in a screen performed 24 hours after transfec-
tion [10], whereas genes in our study were identified 48 hours
after transfection and in the presence of TNF or IL1. A more
likely possibility is that they can either negatively or positively
modulate NFκB, depending on the cellular context. There are
numerous examples of differential gene function depending
on cellular context [15-19], and this behavior has also been
observed for genes within the NFκB network [20,21]. For
example, TRAF2 has been previously shown to play a positive
role in CD40 signaling in B cells and a negative role in TNF
signaling in macrophages [21]. The mechanism underlying
these different behaviors has not been conclusively identified,
Flowchart outlining the steps in the gain-of-function and loss-of-function genomic screens Figure 1
Flowchart outlining the steps in the gain-of-function and loss-of-function genomic screens. The gain-of-function screen was used to identify positive 
modifiers of the NFκB signaling pathway and the loss-of-function screen was used to identify negative modifiers. Approximately 14,500 full-length human 
and mouse genes were screened for activity.
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Functional classification of the NFκB modulators identified in the functional genomic screens Figure 2
Functional classification of the NFκB modulators identified in the functional genomic screens. Functional classification was performed using NIH David 2.1. 
(a) Classification of the positive modulators. (b) Classification of the negative modulators.
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but it has been suggested that it can both activate and degrade
proteins by attaching distinct types of polyubiquitin chains
[22]. In addition, activation of the IKK complex can have pro-
apoptotic or anti-apoptotic effects, depending on timing and
mechanism of activation [20]. Therefore, it is possible that a
cell-based, genomic screen would identify differential behav-
iors for true modulators of NFκB under different treatment
conditions (that is, untreated cells to identify positive modu-
lators and cells treated with TNF or IL1 to identify negative
modulators).
Tissue expression of the NFκB modulators
To obtain a general understanding of how the positive and
negative NFκB modulators were co-expressed across various
tissues, gene-expression data from 79 different tissues was
obtained from Symatlas [23]. The mean expression level and
a 99% confidence interval for each modulator were then cal-
culated across the 79 human tissues. Using the lower 99%
confidence limit as a cutoff, modulators that fell below the
cutoff were considered absent in that tissue, whereas those
that were expressed above the cutoff were considered present.
As expected, tissues involved in the immune response (for
example, peripheral blood BDCA4+  dendritic cells) had a
higher average number of positive and negative modulators
present in the tissue when compared with non-immune tissue
(152 versus 108; p < 0.0001) (Figure 3). These results suggest
that regulation by these modulators is not distributed uni-
formly across tissues and that one mechanism for controlling
the number of branches in the NFκB network is through dif-
ferential expression. This mechanism has been described pre-
viously for G-protein-coupled receptors [24]. Notably, the
number of positive and negative modulators that were
present in a given tissue was highly correlated (r = 0.944; p <
0.001) suggesting that the degree of positive regulation is
counterbalanced by negative regulators at the tissue level.
Contextual organization of the positive NFκB 
modulators
To map the positive modulators within the NFκB structural
network, the effects of each modulator was examined in the
presence of a series of dominant-negative mutants. These
mutants were chosen due to their roles and relative locations
within the NFκB network. Individual positive modulators
were screened in triplicate with IKBKB, IKBKG, TRAF2, and
MAP3K7 (TAK1) dominant-negative mutants (Additional
data file 3). If the activation of the NFκB reporter was blocked
by the dominant-negative mutant (≥ 70% average reduction),
the positive modulator was considered upstream of the dom-
inant-negative mutant. The results from this analysis organ-
ized the positive modulators into four distinct groups -
upstream of TRAF2, upstream of MAP3K7, upstream of the
IKK complex, and no inhibition by any dominant-negative
mutant (Figure 4).
The group of positive modulators identified as upstream of
TRAF2 included a variety of genes with a known dependence
on TRAF2 for signal propagation. They included genes for
several TNF receptors (for example, TNFRSF1A, TNFRSF1B,
and TNFRSF12A), and for LTA, FADD, BIRC2, RIPK3, and
CD40. Of these genes, the FADD protein is known be a part of
a complex that includes TRAF2, RIPK1, and TRADD [25]. For
BIRC2, physical interaction with TRAF2 alters nuclear trans-
location of the protein [26] and a dominant-negative TRAF2
has been demonstrated to inhibit RIPK3 signaling [27]. Other
genes in this group have been associated with NFκB signal-
ing, but have not previously been identified as TRAF2-
dependent. These included PYCARD, TMEM9B, and TIRAP
[10,28,29]. For TIRAP, previous reports have shown that it is
involved in Toll-like receptor signaling [29], raising questions
about its dependence on TRAF2. One explanation is that the
overexpression of the TRAF2 dominant-negative mutant
results in a nonspecific inhibition of TRAF6. However, nei-
ther MYD88 nor any of the Toll-like receptors that were also
identified as positive modulators were inhibited by the over-
expression of the TRAF2 mutant. Another explanation is that
the physical association identified between TBK1 and TIRAP
[30] is part of a larger complex that also includes TRAF2.
TRAF2 has also been shown to associate with TBK1 [31] and
formation of the larger complex may be required for TIRAP
signaling.
In the group of positive modulators identified as acting
upstream of MAP3K7, several genes have a known depend-
ence on MAP3K7 for signaling, including MAP3K7IP2 and
CARD4 (Figure 4). Of the proteins encoded by these genes,
MAP3K7IP2 activates MAP3K7 by forming a complex with
TRAF6, MAP3K7 and TAB1 [32]. CARD4 has been shown to
induce transcription of MAP3K7 and of the genes for other
components of the IL1/TLR branch leading to activation of
NFκB [33]. Other genes in this group have been associated
with NFκB signaling, but not previously identified as
MAP3K7-dependent. These included PAK4, NUTF2, RRAS,
EEF1A1,  TRAF5,  TBL1X,  PYCARD,  ATP2A2,  TMEM9B,
TRAF2, and TNFRSF12A. For TRAF2 and TRAF5, previous
reports have linked their involvement with the TNF signaling
branch [34,35]. However, other reports have shown that
TRAF2 can activate MAP3K7 under certain conditions
[12,36] and that MAP3K7 still contributes to IκB phosphor-
ylation under TNF stimulation [37], suggesting that signaling
through each branch is not exclusive. This cross-talk may
contribute to the number of genes that were found to be
upstream of both TRAF2 and MAP3K7 (Figure 4, green text).
For the positive modulators inhibited by either the TRAF2 or
MAP3K7 dominant-negative mutant, all genes were also
inhibited by at least one of the IKK mutants. For the genes
identified as upstream of TRAF2, MAP3K7, and the IKK com-
plex, the majority was inhibited by both the IKBKB and
IKBKG dominant-negative mutants, and all genes required
IKBKB for activation. This suggests that most of the positive
modulators were from what has historically been referred to
as the canonical branch. Interestingly, five positive modula-R104.6 Genome Biology 2007,     Volume 8, Issue 6, Article R104       Halsey et al. http://genomebiology.com/2007/8/6/R104
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Tissue expression of positive and negative NFκB modulators Figure 3
Tissue expression of positive and negative NFκB modulators. Gene-expression data for 79 human tissues using the human Affymetrix U133A array was 
obtained from Symatlas [23]. The mean expression level and a 99% confidence interval for each gene were then calculated across all 79 human tissues. 
Using the lower 99% confidence limit as a cutoff, modulators that fell below the cutoff were considered absent in that tissue while those that were 
expressed above the cutoff were considered present. The black bars represent the number of positive modulators present in a given tissue out of 131 that 
were contained on the microarray. The light-gray bars represent the number of negative modulators present in a given tissue out of 80 that were 
contained on the microarray. The number of positive and negative modulators significantly expressed in each tissue was significantly correlated (r = 0.944, 
p < 0.001).
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tors were not inhibited by the IKBKG dominant-negative
mutant: they comprise three of the genes upstream of
MAP3K7 and two of the genes upstream of the IKK complex
(Figure 4, red type). The IKBKG dominant-negative mutant
used in the analysis is deficient for binding to CHUK and
IKBKB [38], suggesting that IKBKG binding within the IKK
complex is not required for NFκB activation by these genes.
The group of positive modulators identified as upstream of
IKBKB and IKBKG was substantially larger than those identi-
fied as upstream of TRAF2 and MAP3K7. This primarily
reflects its importance as point of convergence in the path-
way, as it integrates signals from the various upstream
branches [39]. The size of the group may also have been
inflated as a result of the relatively strict analysis criteria that
may not have correctly identified some genes as TRAF2- or
MAP3K7-dependent. These genes include those for the Toll-
like receptor TLR9, three TNF receptors (TNFRSF10B,
TNFRSF11A, and TNFRSF25), and genes such as TAB3 and
IL1B. The signals from these genes were inhibited by the
Contextual organization of the NFκB positive modulators Figure 4
Contextual organization of the NFκB positive modulators. Organization was determined on the basis of follow-up screens with a series of dominant-
negative mutants (TRAF2, MAP3K7, IKBKB, and IKBKG). If activation of the NFκB reporter was blocked by the dominant-negative mutant (≥ 70% average 
reduction), the positive modulator was considered upstream of the dominant-negative mutant. In the boxes upstream of TRAF2 and MAP3K7, green text 
identifies genes that were inhibited by both the TRAF2 and MAP3K7 dominant-negative mutants. In the boxes upstream of MAP3K7 and the IKK complex, 
red text identifies genes that were inhibited only by the IKBKB mutant. Genes identified as IKBKB specific showed ≥ 70% inhibition by the IKBKB 
dominant-negative mutant and <70% inhibition by the IKBKG dominant-negative mutant. In addition, IKBKB-specific genes were required to show a 
fivefold greater reduction in NFκB activation by the IKBKB dominant-negative mutant as compared with the IKBKG mutant. Those genes that were 
inhibited by both the IKBKB and IKBKG dominant-negative mutants were shown in black text. Genes that were not significantly inhibited by any of the 
dominant-negative mutants are listed in the lower right-hand box and were presumed to act downstream in the pathway or through an independent 
branch.
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TRAF2 or MAP3K7 dominant-negative mutants, but not to
the extent required by the cutoff. Apart from these genes,
other positive modulators that are generally accepted to be
upstream of TRAF2 or MAP3K7 may have slipped into the
IKK group as a result of the branched structure of the net-
work, which would allow the signal to be propagated around
the dominant-negative mutant. For example, MYD88 plays a
central role in IL1/TLR signaling and has been shown to acti-
vate NFκB through both MAP3K7-dependent and -independ-
ent mechanisms [9].
In the final group of positive modulators, six genes were not
found to be upstream of any of the dominant-negative
mutants used in these studies. This group included genes
encoding the components of the NFκB transcription complex
(RELA,  RELB, and NFKB1), an NFκB-inducing kinase
(MAP3K14), a member of the claudin superfamily (CLDN12),
and a relatively uncharacterized gene (C20Orf102). The con-
textual placement of MAP3K14, CLDN12, and C20Orf102 was
difficult to localize as the lack of inhibition by the dominant-
negative mutants could mean that the modulators act
through a separate, independent branch that converges at the
transcriptional complex. For MAP3K14, previous reports are
contradictory, with some investigators demonstrating
MAP3K14 activation of the IKK complex [40-42] whereas
others have reported that MAP3K14 can activate NFκB inde-
pendently of IKBKG through a p38 MAPK-dependent RELA
phosphorylation pathway [43].
Contextual organization of the negative NFκB 
modulators
To assess the relative location of the negative modulators,
each modulator was screened together with a constitutively
active IKBKB mutant (Additional data file 4). If activation of
the NFκB reporter was blocked by the negative modulator (≥
70% reduction), the negative modulator was considered
downstream of the constitutively active mutant. If activation
of the NFκB reporter was not blocked, the negative modulator
was considered unclassified as to its inhibitor influence. For
the group of negative modulators downstream of IKBKB, sev-
eral genes were identified that were previously demonstrated
to inhibit NFκB signaling (Figure 5). These genes include
NFKBIB, NFKBIE, PIAS3, PRKACG, PTGER2, and PTGER4.
The downstream effects of the two IκB genes (NFKBIB, NFK-
BIE) have been well established [2], whereas PIAS3 functions
downstream by binding to RELA and suppressing NFκB-
dependent transcription [44]. The gamma catalytic subunit of
protein kinase A (PRKACG) has been shown to repress NFκB
signaling by phosphorylating the p50 homodimer, which acts
a transcriptional repressor by maintaining DNA binding in
unstimulated cells [45]. Finally, for the PTGER2 and PTGER4
genes, a clear mechanism has not been elucidated, but a
recent report by Akaogi and colleagues [46] showed that the
NFκB-dependent transcription of TNF was inhibited by 70%
in response to activation of prostaglandin E2 and E4
receptors.
Constructing a signaling network map for the NFκB 
modulators
To combine the experimental data into a structural network
representing NFκB signaling, an adjacency matrix was con-
structed based on the orientation flags (that is, upstream,
downstream, or unclassified) from the dominant-negative
and constitutively active screens used in the contextual
organization analysis. The adjacency matrix containing the
experimental data was then merged with a separate adjacency
matrix containing members of the currently accepted NFκB
signaling network. By using the known NFκB network as a
scaffold, we were able to include additional signaling inter-
mediates and create a more hierarchically consistent net-
work. Based on the combined adjacency matrix, a network
map was constructed as a rooted tree with the NFκB complex
serving as the obligate root node. The longest path was calcu-
lated from each terminal node to the root node using a previ-
ously defined algorithm [47]. The inferred NFκB structural
network is provided as an additional data file (Additional data
file 7).
Constructing the NFκB signaling map provides insight into
the potential logic embedded within the network and allows
additional hypotheses to be generated regarding influence
and potential cross-talk from the positive and negative
modulators identified in this investigation. The potential for
positive cross-talk in our investigation was concentrated
upstream of MAP3K7 and directly upstream of IKBKB and
IKBKG. In contrast, a significant number of negative modula-
tors entered the network between the IKK complex and the
activated transcription factor, providing a large number of
modes for negative regulation.
Discussion
Technological advances and the improved annotation of the
human genome have provided a sound foundation for exam-
ining the composition and structure of signaling networks. By
building on currently accepted experimental methodologies,
we were able to develop a functional genomic strategy for
identifying positive and negative modulators of the NFκB sig-
naling network and organize these modulators contextually
within the network structure. The NFκB signaling network
has been well studied, and many of the network components
have been ascribed specific functional roles. Using these pre-
vious observations, we were able to both test the validity of
our functional genomic approach and identify novel compo-
nents and structural features of the network.
The 154 positive modulators and 88 negative modulators that
were identified in the functional genomic screens provide a
better understanding of the breadth of system controls within
the NFκB network. The positive modulators were from a
diverse array of functional categories that reflected the wide
range of stimuli and cross-coupling with the NFκB network,
whereas the negative modulators were less diverse and morehttp://genomebiology.com/2007/8/6/R104 Genome Biology 2007,     Volume 8, Issue 6, Article R104       Halsey et al. R104.9
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focused on downstream processes. Contextual organization
of the modulators and generation of a signaling network map
showed that most of the positive modulators acted upstream
of MAP3K7 and the IKK complex, while fewer were found
upstream of TRAF2. This is consistent with a previous study
that suggested that the majority of cross-talk interactions
within the IL1/TLR branch were concentrated in the region
below MYD88 and TRAF6 [9]. Taken together, these results
are consistent with previous observations that the three IKKs
(CHUK, IKBKB, and IKBKG) represent the point at which the
majority of signals converge in the network [39,48] and serve
as the core of an hourglass or bow-tie structure that is charac-
teristic of many robust systems [9,49,50] (Figure 6).
Differences in the type, level, and temporal activation of the
IKK core is one mechanism that allows the NFκB network to
provide a virtual hyperplane of differential responses from a
wide range of stimuli. For example, the type of activation of
the IKK core through either CHUK homodimers in the atypi-
cal branch or through IKBKB in the canonical branch is one
mechanism for achieving different outputs from a different
set of input signals [2]. In our investigation, we identified a
small subset of the positive modulators that did not require
IKBKG for their effects. It is possible that activation of the
IKK core independent of IKBKG contributes to a different
type of output from the NFκB network. Additional research is
needed to confirm these observations and understand the
context in which this subset of genes participates in NFκB
signaling.
In contrast to the positive modulators, a significant number
of negative modulators were localized downstream of IKBKB.
Notably, these negative modulators inhibited NFκB signaling
in the same general location as the IκB proteins. Hoffmann
and colleagues [51] showed that the individual IκB proteins
function differently in their ability to negatively regulate
NFκB signaling. NFKBIA provides strong negative feedback
that inhibits short-term NFκB responses, whereas NFKBIB
and NFKBIE dampen oscillations in the system and inhibit
NFκB during longer stimulations. The temporal differences
among these IκB proteins generate specificity at the level of
gene activation and provide an additional layer of control
within the NFκB network for generating differential output
from different inputs. Although we do not know the mecha-
nism of negative regulation for many of the modulators iden-
tified in our screen, the fact that they inhibit NFκB signaling
Contextual organization of the NFκB negative modulators Figure 5
Contextual organization of the NFκB negative modulators. Organization was determined on the basis of follow-up screens with an IKBKB constitutively-
active mutant. If activation of the NFκB reporter was blocked by the negative modulator (≥ 70% average reduction), the negative modulator was 
considered downstream of the constitutively active mutant. If activation of the NFκB reporter was not blocked, the negative modulator was considered 
unclassified as to its inhibitor influence.
4632407F12RIK
BDKRB1
GPR3
MATN2
PFDN2
PTGDR
SGK3
TLR7
NFκB
2810405K02RIK
ASPSCR1
BET1L
CREBL1
E2F4
FAM104A
GJB3
GPR161
IKBKG
MAP3K11
MARCH2
NGEF
OSR2
PSMF1
RHOB
SLC43A2
TFAP4
TNK1
TSPAN13
Downstream of IKK
(Downstream of IKBKB constitutively active mutant)
Context of negative effects unclassified
(Not downstream of IKBKB constitutively active mutant)
IKBKB ￿ IKBKG
IL1 TNF
ADORA2A
EDG4
HTR2B
NFKBIB
PIAS3
PTGER2
SIX1
VIPR2
ADRB2
ERF
KLF15
NFKBIE
PRKACG
PTGER4
SLC44A3
ZFP36L1
BARX2
GPD1
MAFF
OVOL1
PRKX
PTHR1
STMN1
ACTG1
BC012487
C20ORF98
D430028G21RIK
ERG
FLJ25477
GJB4
GUCA1B
KIAA0515
MAP3K3
MTF1
NKX2-3
PIAS4
PXN
RHOC
SLC7A5
TFEB
TNK2
UBE2M
AKT2
BCL11B
CPEB1L
DAPK2
EWSR1
FOXP4
GPM6A
GLA-DRB3
KIRREL1
MAPK6
NFKB2
OPN3
PLEKHG5
RHBDL1
SLC22A11
SPIN1
TMOD3
TRAF2
ZBTB16R104.10 Genome Biology 2007,     Volume 8, Issue 6, Article R104       Halsey et al. http://genomebiology.com/2007/8/6/R104
Genome Biology 2007, 8:R104
downstream of the IKK core is highly suggestive that they also
participate as an additional layer of negative control similar
to the IκB proteins. The large number of negative modulators
in this group suggests that this type of control is a relatively
common mechanism within the NFκB network to increase
specificity and diversity in the output.
By comparing the expression of the positive and negative
modulators across tissues, a third control mechanism was
identified. Processes or branches in the network can be added
or subtracted on an individual tissue or cell-type basis. In our
study, the highest numbers of positive and negative modula-
tors were significantly expressed in immune tissues, under-
scoring the need to integrate diverse sets of signals in these
cells from the various upstream branches into decisions on
cell fate, cytokine release, cell adhesion, second messenger
release, and others. The number of positive and negative
modulators that were significantly expressed in each tissue
was highly correlated, suggesting that as the number of
upstream branches increases, so must the number of genes in
the negative control layer downstream of the IKK core.
Conclusion
The application of functional genomic tools in this study has
identified many potential novel modulators of NFκB signal-
ing as well as provided insights into several structural and
regulatory characteristics of the network. The insights build
upon the hourglass architecture that has been proposed by
Kitano and colleagues for a variety of signaling pathways
[49,50,52] and identify additional layers of control for con-
verting a diverse set of input signals to differential outputs
(Figure 6). The additional layers consist of a potential
upstream branch that does not require IKBKG for NFκB acti-
vation, many negative modulators that act downstream of the
core IKK complex, and distribution across tissues of the pos-
itive and negative modulators. The next challenge will be to
understand the cellular context in which the various positive
and negative modulators participate in NFκB signaling and
how these different control layers can be manipulated to treat
specific inflammatory diseases without unwanted side effects.
Materials and methods
cDNA clone collection and construction
A set of bacterial stocks from the Mammalian Gene Collection
(MGC) containing 30,720 cDNA clones in 80 384-well plates
An hourglass model of the NFκB signaling network representing the multiple controls within the system that allow differential responses to diverse stimuli Figure 6
An hourglass model of the NFκB signaling network representing the multiple controls within the system that allow differential responses to diverse stimuli. 
The hourglass shape is characteristic of many robust systems in biology. At the top of the hourglass, the numerous signaling branches and inputs from 
cross-talk are funneled into the central core regulated by the IKKs. The IKKs integrate these signals to produce a wide-range of cellular responses that are 
specific to the stimuli. The specificity and diversity are achieved at multiple levels of regulation within the hourglass model (red text). Tissue expression 
add or subtract inputs to the model depending on which processes are needed in a given cell type. The IKK core regulates responses based on the type, 
level, and temporal nature of the activation. Negative regulators downstream of the IKK core represent a third level of control.
Positive
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IKK Tissue
E
Diverse signaling inputs
Negative
modulators
Differential outputs
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were ordered from the American Type Culture Collection
(Manassas, VA). Putative full-length mouse and human
cDNA clones in mammalian expression vectors were identi-
fied by cross-referencing the library with the 'Static Clone
List' generated by MGC [53] and the 'IRAK/IRAL Cumulative
File' generated by the IMAGE consortium [54] from which
the MGC set is derived. Full-length status was determined by
the MGC and IMAGE consortium through end sequencing,
and full-length clones were given a GenBank identifier. The
bacterial stocks for the cDNA clones matching the full-length
criteria and cloned in mammalian expression vectors were
rearrayed using a Genetix Q-bot (Hampshire, UK) into 96-
well plates. A total of 8,700 full-length mouse and 5,800 full-
length human genes were rearrayed. The rearrayed bacterial
clones were amplified using a Hi-Gro incubator (Genomic
Solutions, Ann Arbor, MI) in deep-well, 96-well plates con-
taining 1.5 ml of Terrific Broth plus antibiotic (20 h; 500
rpm). Plasmid DNA was isolated from the bacterial clones
and purified using a Roboprep 2500 (MWG, High Point, NC)
and Macherey-Nagel NucleoSpin Robot-96 kits (Macherey-
Nagel, Easton, PA). After purification, DNA concentrations
were quantified on the basis of absorbance at 260 nm and
normalized to a standard concentration of 2 ng/μl using a
Theonyx liquid-handling robot (MWG). Individual clones
were sequenced at random to verify gene inserts using univer-
sal M13 sequencing primers.
Cell culture and plasmids
Human embryonic kidney (HEK)-293T cells were obtained
from the American Type Culture Collection (ATCC No. CRL-
11268, Rockville, MD) and were grown in Dulbecco's Modi-
fied Eagle Medium supplemented with 10% fetal bovine
serum and 100 U/ml penicillin-streptomycin (Invitrogen,
Carlsbad, CA). Cells were maintained at 37°C with 5% CO2 in
a humidified chamber. The plasmids used in this study were
from the following sources: pNFκB-Luc (5X TGGGGACTT-
TCCGC) and pGRE-Luc (Stratagene, La Jolla, CA); pCMV-
Sport6-Empty and pUC18-Empty (Invitrogen); pCS2-DsRed
(kindly provided by R. Davis); pCMX-IKBKB SS-AA (Ser177A
& Ser181A) and pCMX-IKBKB SS-EE (Ser177E & Ser181E)
(kindly provided by S. Chanda); pCMV-MAP3K7 (K63W)
(kindly provided by J. Ninomiya-Tsuji); pCMV-ΔTRAF2 (1-
211) (kindly provided by G. Natoli); and pcDNA3-HA-IKBKG
(134-419) (kindly provided by G. Nuñez).
High-throughput transfection and assay conditions
High-throughput transfections for the gain-of-function
screens were performed in 384-well plates with each well
containing 20 μl OptiMEM with GlutaMax (no serum or anti-
biotic), 20 ng pNFκB-Luc, 15 ng pCS2-DsRed, and 150 nl
Fugene6 (Roche Diagnostics, Indianapolis, IN). The transfec-
tion mix was dispensed using a Multidrop-384 (Titertek,
Huntsville, AL). Purified plasmid DNA (15 ng) for each gene
was added to an individual well of a 384-well plate using a
Biomek FX robot (Beckman Coulter, Fullerton, CA) and the
DNA:Fugene mixture was incubated for 30 min at room tem-
perature. Each 384-well plate contained eight empty wells for
the manual addition of positive and negative control plas-
mids. A pCMV-Sport6-Empty plasmid lacking a cDNA insert
was included in each plate as the negative control. Following
incubation, HEK-293T cells were added to each well in 20 μl
serum-containing medium (20% fetal bovine serum, 200 U/
ml penicillin-streptomycin) at a concentration of 400,000
cells/ml. The plates were then incubated for 48 h at 37°C with
5% CO2. At the end of the incubation period, 40 μl BriteLite
(Perkin Elmer, Wellesley, MA) was added to each well using
the Multidrop-384 (Titertek). Within 5 min after substrate
addition, luminescence and fluorescence were read using an
Analyst HT plate reader (Molecular Devices, Sunnyvale, CA).
For the loss-of-function screens, transfections were per-
formed identically to the gain-of-function screens except that
either purified TNF or IL1B (Sigma Aldrich, St. Louis, MO;
Catalog Nos. T0157 and I9401) was added in 10 μl medium, 4
h post-transfection. The concentrations of TNF and IL1B
were 20 ng/ml (final) and 0.5 ng/ml (final), respectively.
To contextually organize the positive NFκB modulators, each
combinatorial screen was run using paired 384-well plates. In
one of the paired plates, the positive modulators were co-
transfected with either 15 or 20 ng of the dominant-negative
expression plasmid. Fifteen ng of the dominant-negative
expression plasmid was used for pCMV-ΔTRAF2 and pCMV-
MAP3K7 (K63W) while 20 ng was used for pCMX-IKBKB SS-
AA and pcDNA3-HA-IKBKG (134-419). In the second paired
plate, the positive modulators were co-transfected with either
15 ng or 20 ng of pUC18-Empty to match the amount of the
dominant-negative expression plasmid. The pUC18-Empty
was used as a control for the dominant-negative mutant to
keep the total amount of DNA constant. Both of the paired
384-well plates contained eight empty wells for manual addi-
tion of positive and negative control plasmids. A pCMV-
Sport6-Empty plasmid was included on each paired plate as
the negative control for the positive modulator. Assay condi-
tions were identical to those described for the gain-of-func-
tion screen except that the amount of Fugene6 (Roche
Diagnostics) was increased to either 195 nl (TRAF2,
MAP3K7) or 210 nl (IKBKB, IKBKG). To contextually organ-
ize the negative NFκB modulators, paired 384-well plates
were also used. In one of the paired plates, the negative mod-
ulator was co-transfected with 10 ng of the pCMX-IKBKB SS-
EE plasmid expressing the IKBKB constitutively active
mutant. In the second paired plate, the negative modulators
were co-transfected with 10 ng pUC18-Empty. The pUC18-
Empty was used as a control for the constitutively active
mutant to keep the total amount of DNA constant. Both of the
paired 384-well plates contained eight empty wells for man-
ual addition of positive and negative control plasmids. A
pCMV-Sport6-Empty plasmid was included on each paired
plate as the negative control for the negative modulator.
Assay conditions were identical to those described for the
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(Roche Diagnostics) was increased to 180 nl. Each paired
combinatorial screen was performed at least three times.
Analysis of the gain-of-function and loss-of-function 
screening data
Luciferase measurements for each gene in the gain-of-func-
tion and loss-of-function screens were adjusted for
background luminescence using control wells containing only
media and BriteLite (PerkinElmer). The background-sub-
tracted values were then normalized for transfection effi-
ciency using the fluorescent DsRed measurements.
Normalized fold-change ratios were calculated by dividing
the normalized luciferase values for each gene by the normal-
ized luciferase values for the pCMV-Sport6-Empty negative
control on each plate. In the case where multiple control wells
on each plate were transfected with the pCMV-Sport6-Empty
plasmid, the average normalized luminescence value was
used to calculate the normalized fold-change ratio. In the ini-
tial gain-of-function screen, significant positive modulators
were required to have a normalized fold-change ratio greater
than three-fold and luminescence values greater than 5
standard deviations (SD) from the experimental mean. In the
initial loss-of-function screen, significant negative modula-
tors were required to have a normalized fold-change ratio less
than 0.34 (that is, > 3-fold reduced) and luminescence values
less than 5 SD from the experimental mean. Confirmation
assays on the significant positive and negative modulators
were performed at least three times and analyzed using a one-
sample t-test for its statistical significance from a fold change
of 1. Probability values were adjusted for multiple compari-
sons using a false-discovery rate correction [55]. Confirmed
hits were required to have an average normalized fold-change
ratio greater than three-fold (positive modulators) or less
than 0.34 (negative modulators) and an adjusted p value <
0.05.
Functional analysis of the positive and negative modulators
was performed using NIH David 2.1 [56] and based on molec-
ular function ontologies at level 2. Mapping of positive and
negative modulators to the known signaling pathways was
performed using GenMAPP 2.1 [57]. The canonical TNF, IL1,
B-cell receptor, and T-cell receptor signaling pathways were
obtained from the Human Protein Reference Database [58].
Analysis of tissue expression
Gene-expression data for 79 human tissues using the human
Affymetrix U133A array were obtained from Symatlas [23].
The raw data were preprocessed using GCRMA with a log2
transformation. The mean expression level and a 99% confi-
dence interval for each gene were then calculated across all 79
human tissues. Using the lower 99% confidence limit as a cut-
off, modulators that fell below the cutoff were considered
absent in that tissue, whereas those that were expressed
above the cutoff were considered present. Statistical analysis
of the average number of modulators present in immune tis-
sue versus non-immune tissue was performed using a two-
sample t-test.
Analysis of the combinatorial screens to contextually 
organize positive and negative modulators
Combinatorial screens for the positive modulators were ana-
lyzed by first subtracting background luminescence values
and normalizing for transfection efficiency using the fluores-
cent DsRed measurements. Normalized fold-change ratios
were calculated for each positive modulator on each of the
paired 384-well plates by dividing the normalized luciferase
values by the normalized luciferase values for the pCMV-
Sport6-Empty negative control. A percent reduction was
calculated based on the normalized fold-change ratio of the
positive modulator that was co-transfected with the domi-
nant-negative mutant and the normalized ratio of the positive
modulator that was co-transfected with pUC18-Empty. The
percentage reduction by the dominant-negative mutant was
averaged for at least three experimental replicates and then
subjected to a lower-bound cutoff that flagged each positive
modulator as either upstream or unclassified relative to the
dominant-negative mutant. A lower-bound cutoff of ≥ 70%
was used to flag positive modulators as upstream. Percent
reductions less than the cutoff were flagged as unclassified.
Analysis of the combinatorial screens for the negative modu-
lators was performed similarly, except that modulators show-
ing ≥ 70% reduction were flagged as downstream relative to
the constitutively active mutant and all others were flagged as
unclassified.
Signaling network construction
An adjacency matrix was constructed based on the orienta-
tion flags (that is, upstream, downstream, or unclassified)
from the dominant-negative and constitutively active screens
used in the contextual organization analysis. The adjacency
matrix containing the experimental data was then merged
with a separate adjacency matrix containing the known NFκB
signaling network. On the basis of the combined adjacency
matrix a signaling network map was constructed as a rooted
tree with the NFκB complex serving as the obligate root node.
The longest path was calculated from each terminal node to
the root node using a previously defined algorithm [47]. For
example, if A is upstream of B and C, and B is upstream of C
but downstream of A, then the graph would be drawn as A →
B → C and not as A → B, A → C and B → C. The signaling net-
works were visualized using Cytoscape software [59].
Additional data files
The following additional data are available online with this
paper. Additional data file 1 is a table containing a complete
list of positive NFκB modulators identified using the gain-of-
function full-length gene screens. Additional data file 2 is a
table containing a complete list of negative NFκB modulators
identified using the loss-of-function full-length gene screens.
Additional data file 3 is a table listing the reduction in NFκBhttp://genomebiology.com/2007/8/6/R104 Genome Biology 2007,     Volume 8, Issue 6, Article R104       Halsey et al. R104.13
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activation by the positive modulators using the IKBKB,
IKBKG, MAP3K7, and TRAF2 dominant-negative mutants.
Additional data file 4 is a table listing the reduction in NFκB
activation by a constitutively active IKBKB mutant using the
negative NFκB modulators. Additional data file 5 is a figure of
the overlap and location of positive and negative modulators
identified in the cell-based screens within the canonical TNF
(A) and IL1 (B) signaling pathways. The signaling pathways
were obtained from the Human Protein Reference Database
and visualized using GenMAPP 2.1. The green shaded boxes
represent positive modulators and red shaded boxes repre-
sent negative modulators. Green shaded boxes with red bor-
ders represent modulators that were identified as both
positive and negative. Additional data file 6 is a figure show-
ing the overlap and location of positive and negative modula-
tors identified in the cell-based screens within the canonical
B-cell receptor (A) and T-cell receptor (B) signaling path-
ways. The signaling pathways were obtained from the Human
Protein Reference Database and visualized using GenMAPP
2.1. The green shaded boxes represent positive modulators
and red shaded boxes represent negative modulators. Green
shaded boxes with red borders represent modulators that
were identified as both positive and negative. Additional data
file 7 is a figure showing a network map of the NFκB
modulators. An adjacency matrix was constructed on the
basis of the orientation flags from the dominant-negative and
constitutively active screens (that is, upstream, downstream,
or unclassified). The adjacency matrix containing the experi-
mental data was merged with a separate adjacency matrix
containing members of the currently accepted NFκB signal-
ing network. On the basis of the combined adjacency matrix,
a network map was constructed as a rooted tree with the
NFκB complex serving as the obligate root node. The longest
path was calculated from each terminal node to the root node.
Peach nodes = positive modulators; green nodes = negative
modulators; pink nodes = genes identified as both positive
and negative modulators; orange nodes = members of the
known NFκB signaling network; red nodes = dominant-neg-
ative mutants (plus TRAF2); blue nodes = positive modula-
tors whose network location was adjusted based on the
currently accepted NFκB network structure.
Additional data file 1 Supplemental Table 1 A complete list of positive NFκB modulators identified using the  gain-of-function full-length gene screens. Click here for file Additional data file 2 Supplemental Table 2 A complete list of negative NFκB modulators identified using the  loss-of-function full-length gene screens. Click here for file Additional data file 3 Supplemental Table 3 A table listing the reduction in NFκB activation by the positive  modulators using the IKBKB, IKBKG, MAP3K7, and TRAF2 domi- nant-negative mutants. Click here for file Additional data file 4 Supplemental Table 4 A table listing the reduction in NFκB activation by a constitutively  active IKBKB mutant using the negative NFκB modulators. Click here for file Additional data file 5 Supplemental Figure 1 A figure of the overlap and location of positive and negative modu- lators identified in the cell-based screens within the canonical TNF  (A) and IL1 (B) signaling pathways. The signaling pathways were  obtained from the Human Protein Reference Database and visual- ized using GenMAPP 2.1. The green shaded boxes represent posi- tive modulators and red shaded boxes represent negative  modulators. Green shaded boxes with red borders represent mod- ulators that were identified as both positive and negative. Click here for file Additional data file 6 Supplemental Figure 2 A figure showing the overlap and location of positive and negative  modulators identified in the cell-based screens within the canoni- cal B-cell receptor (A) and T-cell receptor (B) signaling pathways.  The signaling pathways were obtained from the Human Protein  Reference Database and visualized using GenMAPP 2.1. The green  shaded boxes represent positive modulators and red shaded boxes  represent negative modulators. Green shaded boxes with red bor- ders represent modulators that were identified as both positive and  negative. Click here for file Additional data file 7 Supplemental Figure 3 A figure showing a network map of the NFκB modulators. An adja- cency matrix was constructed on the basis of the orientation flags  from the dominant-negative and constitutively active screens (that  is, upstream, downstream, or unclassified). The adjacency matrix  containing the experimental data was merged with a separate adja- cency matrix containing members of the currently accepted NFκB  signaling network. Based on the combined adjacency matrix, a net- work map was constructed as a rooted tree with the NFκB complex  serving as the obligate root node. The longest path was calculated  from each terminal node to the root node. Peach nodes = positive  modulators; green nodes = negative modulators; pink nodes =  genes identified as both positive and negative modulators; orange  nodes = members of the known NFκB signaling network; red nodes  = dominant-negative mutants (plus TRAF2); blue nodes = positive  modulators whose network location was adjusted based on the cur- rently accepted NFκB network structure. Click here for file
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